Introduction: Migraine usually ameliorates after menopause. However, 10–29% of women still experience migraine attacks after menopause, especially if menopause is surgical. The use of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) is changing the landscape of migraine treatment. This study aims to explore the effectiveness and safety of anti-CGRP monoclonal antibodies in women in menopause. Methods: Women affected by either migraine or chronic migraine and treated with an anti-CGRP monoclonal antibody for up to 1 year. Visits were scheduled every 3 months. Results: Women in menopause displayed a similar response compared to women of childbearing age. Among women in menopause, the women experiencing surgical menopause seemed to exhibit a similar response compared to the ones experiencing physiological menopause. Erenumab and galcanezumab displayed similar effectiveness in women in menopause. No serious adverse events were registered. Discussion: The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies.
Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study / Guerzoni, Simona; Baraldi, Carlo; Brovia, Daria; Cainazzo, Maria Michela; Lo Castro, Flavia; Pani, Luca. - In: ACTA NEUROLOGICA BELGICA. - ISSN 0300-9009. - 123:3(2023), pp. 1039-1047. [10.1007/s13760-023-02190-5]
Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study
Simona Guerzoni;Carlo Baraldi;Daria Brovia;Maria Michela Cainazzo;Flavia Lo Castro;Luca Pani
2023
Abstract
Introduction: Migraine usually ameliorates after menopause. However, 10–29% of women still experience migraine attacks after menopause, especially if menopause is surgical. The use of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) is changing the landscape of migraine treatment. This study aims to explore the effectiveness and safety of anti-CGRP monoclonal antibodies in women in menopause. Methods: Women affected by either migraine or chronic migraine and treated with an anti-CGRP monoclonal antibody for up to 1 year. Visits were scheduled every 3 months. Results: Women in menopause displayed a similar response compared to women of childbearing age. Among women in menopause, the women experiencing surgical menopause seemed to exhibit a similar response compared to the ones experiencing physiological menopause. Erenumab and galcanezumab displayed similar effectiveness in women in menopause. No serious adverse events were registered. Discussion: The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies.File | Dimensione | Formato | |
---|---|---|---|
s13760-023-02190-5.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
1.6 MB
Formato
Adobe PDF
|
1.6 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris